Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to advancing global health through the provision of high-quality pharmaceutical intermediates. Tazemetostat, a critical component in cutting-edge cancer therapies, is one such compound. As a selective EZH2 inhibitor, it represents a significant development in the treatment of challenging malignancies, particularly rare sarcomas and certain lymphomas.
The discovery and application of EZH2 inhibitors have revolutionized targeted oncology. EZH2, or Enhancer of Zeste Homolog 2, is an enzyme that plays a vital role in cell development and is often found to be dysregulated in cancer. By inhibiting EZH2, Tazemetostat can help to control the growth of cancer cells that rely on this pathway. This targeted approach, focusing on specific tazemetostat EZH2 inhibitor mechanisms, allows for more effective treatment with potentially fewer side effects compared to traditional chemotherapy.
Epithelioid sarcoma is a rare and often aggressive soft-tissue cancer. For many years, treatment options were limited, and patient outcomes were often poor. The introduction of Tazemetostat has brought about a new era in epithelioid sarcoma treatment. Its approval signifies a major milestone, offering a personalized treatment option that directly addresses the underlying molecular characteristics of the tumor. This targeted therapy provides a much-needed alternative for patients facing this challenging diagnosis.
In addition to its use in sarcoma, Tazemetostat is also making an impact in the treatment of follicular lymphoma. Specifically, for patients whose follicular lymphoma exhibits EZH2 mutations, Tazemetostat offers a tailored therapeutic strategy. This precision medicine approach, targeting the follicular lymphoma EZH2 mutation, maximizes the drug's effectiveness and aligns with the growing trend towards personalized cancer care. Identifying patients with this specific genetic alteration is key to unlocking the full potential of this therapy.
NINGBO INNO PHARMCHEM CO.,LTD. is proud to be a reliable supplier of Tazemetostat, contributing to the availability of these advanced treatments. The ongoing research into the EZH2 gene and its role in various cancers continues to reveal new therapeutic possibilities. Tazemetostat is not just a chemical compound; it is a testament to the power of molecularly targeted therapies in transforming patient care and improving outcomes in the fight against cancer. The future of cancer treatment is increasingly focused on such precision-driven approaches.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
